They provide the necessary infrastructure—including mammalian and microbial expression systems —to ensure that experimental compounds like KBI-092 meet strict GMP (Good Manufacturing Practice) standards for human testing. Description Primary Code Drug Class Small molecule antineoplastic; Dual Kinase Inhibitor Targets FLT3 and IRAK4 Primary Indication Relapsed/Refractory Acute Myeloid Leukemia (RR-AML) Administration Oral tablet, twice daily (BID) Trial Phase Phase 1 (First-in-Human)
Unlike traditional therapies that target a single pathway, KBI-092 is engineered for a "two-pronged" attack on leukemia cells. Its therapeutic efficacy stems from the selective inhibition of two critical proteins:
As of late 2025, KBI-092 has moved into the active clinical testing phase: KBI-092
The drug has received clearance from both the FDA (United States) and the NMPA (China) to begin Phase 1 clinical trials.
By inhibiting both FLT3 and IRAK4 simultaneously, KBI-092 aims to overcome the "bypass mechanisms" cancer cells use to survive when only one pathway is blocked. By inhibiting both FLT3 and IRAK4 simultaneously, KBI-092
Developed primarily by , KBI-092 (HPB-092) is a novel dual-kinase inhibitor designed to disrupt survival signals that allow cancer cells to resist standard treatments. The Mechanism of Action: Dual Inhibition
This protein is a central mediator in the toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) signaling pathways. These pathways are frequently hijacked by cancer cells to promote inflammation and evade cell death, particularly in patients who have failed prior FLT3 inhibitor therapy. These pathways are frequently hijacked by cancer cells
The ongoing research into KBI-092 represents a shift toward more sophisticated, multi-targeted therapies that address the inherent complexity and adaptability of blood cancers. HPB 092 - AdisInsight
The development of KBI-092 involves high-level collaboration within the biopharmaceutical ecosystem. , a leading global Contract Development and Manufacturing Organization (CDMO) , is frequently involved in scaling the production of complex biologics and small molecules for clinical trials.